Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 2/20 | 0.73 |
| ▸ | DRD1 | P21728 | 13/20 | 0.60 |
| ▸ | DRD2 | P14416 | 11/20 | 0.60 |
| ▸ | DRD3 | P35462 | 2/20 | 0.60 |
| ▸ | DRD5 | P21918 | 1/20 | 0.60 |
| ▸ | MAOA | P21397 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CASP1 | P29466 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | APAF1 | O14727 | 1/20 | 0.50 |
| ▸ | BCHE | P06276 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29365732 | 0.97 | HTR1A (0.73) | HTR1ADRD1DRD2DRD3DRD5 | |
| Argemonine SCHEMBL3865650 | 0.87 | HTR1A (0.58) | HTR1ADRD1DRD2DRD3DRD5 | |
| Argemonine SCHEMBL30435899 | 0.87 | HTR1A (0.58) | HTR1ADRD1DRD2DRD3DRD5 | |
| Caryachine SCHEMBL6376741 | 0.85 | HTR1A (1.00) | HTR1ADRD1DRD2DRD3DRD5 | |
| Caryachine SCHEMBL29350783 | 0.85 | HTR1A (1.00) | HTR1ADRD1DRD2DRD3DRD5 | |
| SCHEMBL14703870 | 0.76 | DRD1 (1.00) | HTR1ADRD1DRD2DRD3DRD5 | |
| SCHEMBL14703833 | 0.76 | DRD1 (1.00) | HTR1ADRD1DRD2DRD3DRD5 | |
| SCHEMBL30298995 | 0.76 | DRD1 (1.00) | HTR1ADRD1DRD2DRD3DRD5 | |
| SCHEMBL14703834 | 0.76 | DRD1 (1.00) | HTR1ADRD1DRD2DRD3DRD5 | |
| Coreximine SCHEMBL30473249 | 0.76 | DRD1 (1.00) | HTR1ADRD1DRD2DRD3DRD5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260103736-A1 | Methods Of Improving Production Of Morphinan Alkaloids And Derivatives | ANTHEIA INC (US) | 2026-04-16 | — | — | US | disclosed |
| US-12497638-B2 | Methods of producing epimerases and benzylisoquinoline alkaloids | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2025-12-16 | — | — | US | disclosed |
| EP-3221461-B1 | NOSCAPINOID-PRODUCING MICROBES AND METHODS OF MAKING AND USING THE SAME | UNIV LELAND STANFORD JUNIOR (US) | 2025-01-01 | — | — | EP | disclosed |
| US-20240218408-A1 | Methods of Producing Epimerases and Benzylisoquinoline Alkaloids | HERCULES CAPITAL, INC., AS AGENT | 2024-07-04 | — | — | US | disclosed |
| US-11859225-B2 | Methods of producing epimerases and benzylisoquinoline alkaloids | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2024-01-02 | — | — | US | disclosed |
| EP-4247937-A1 | METHODS OF IMPROVING PRODUCTION OF MORPHINAN ALKALOIDS AND DERIVATIVES | Antheia, Inc. (US) | 2023-09-27 | — | — | EP | disclosed |
| US-20230203551-A1 | Noscapinoid-producing Microbes and Methods of Making and Using the Same | HERCULES CAPITAL, INC., AS AGENT | 2023-06-29 | — | — | US | disclosed |
| EP-3294865-B1 | METHODS OF PRODUCING EPIMERASES AND BENZYLISOQUINOLINE ALKALOIDS | UNIV LELAND STANFORD JUNIOR (US) | 2023-04-12 | — | — | EP | disclosed |
| US-11427827-B2 | Engineered benzylisoquinoline alkaloid epimerases and methods of producing benzylisoquinoline alkaloids | ANTHEIA, INC. (US) | 2022-08-30 | — | — | US | disclosed |
| WO-2022109194-A1 | METHODS OF IMPROVING PRODUCTION OF MORPHINAN ALKALOIDS AND DERIVATIVES | ANTHEIA, INC. (US) | 2022-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260103736-A1 | Methods Of Improving Production Of Morphinan Alkaloids And Derivatives | OPRK1, OPRM1, OPRD1 | HTR1A 94/4885DRD1 532/4885DRD2 618/4885 |
| US-20230203551-A1 | Noscapinoid-producing Microbes and Methods of Making and Using the Same | NOS2, NISCH, NOS1 | HTR1A 1035/4885DRD1 653/4885DRD2 641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.